Quantitative cumulative biodistribution of antibodies in mice: Effect of modulating binding affinity to the neonatal Fc receptor

mAbs

Volumn 6, Issue 3, 2014, Pages 689-696

  Yip, Victor ^a   Palma, Enzo ^a   Tesar, Devin B ^a   Mundo, Eduardo E ^a   Bumbaca, Daniela ^a   Torres, Elizabeth K ^a   Reyes, Noe A ^a   Shen, Ben Q ^a   Fielder, Paul J ^a   Prabhu, Saileta ^a   Khawli, Leslie A ^a,b   Boswell, C Andrew ^a  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Biodistribution; FcRn; Indium; Metabolism; Pharmacokinetics; Radiolabeled

Indexed keywords

FC RECEPTOR; GLYCOPROTEIN D; IMMUNOGLOBULIN G1 ANTIBODY; INDIUM 111; IODINE 125; IMMUNOGLOBULIN G; INDIUM; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHO CELL LINE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; GENETIC ENGINEERING; HEART; HERPES SIMPLEX VIRUS; KIDNEY; LARGE INTESTINE; LUNG; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; SKIN; SMALL INTESTINE; SPLEEN; STOMACH; SURFACE PLASMON RESONANCE; ANIMAL; CRICETULUS; FEMALE; GENETIC VARIATION; GENETICS; HAMSTER; HUMAN; METABOLISM; MOUSE; NEWBORN; PROTEIN DEGRADATION; TISSUE DISTRIBUTION;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL, HUMANIZED; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; GENETIC VARIATION; HUMANS; IMMUNOGLOBULIN G; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; MICE; PROTEOLYSIS; RECEPTORS, FC; TISSUE DISTRIBUTION;

EID: 84899741811     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.28254     Document Type: Article

References (50)

1. Sidhu SS. Full-length antibodies on display. Nat Biotechnol 2007; 25:537-8; PMID:17483836; http://dx.doi.org/10.1038/nbt0507-537
2. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2003; 2:52-62; PMID:12509759; http://dx.doi.org/10.1038/nrd984
3. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93:2645-68; PMID:15389672; http://dx.doi.org/10.1002/jps.20178
4. Kim JK, Tsen MF, Ghetie V, Ward ES. Catabolism of the murine IgG1 molecule: evidence that both CH2-CH3 domain interfaces are required for persistence of IgG1 in the circulation of mice. Scand J Immunol 1994; 40:457-65; PMID:7939418; http://dx.doi.org/10.1111/j.1365-3083.1994.tb03488.x
5. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-25; PMID:17703228; http://dx.doi.org/10.1038/nri2155
6. Ober RJ, Martinez C, Vaccaro C, Zhou J, Ward ES. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol 2004; 172:2021-9; PMID:14764666
7. Junghans RP. Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res 1997; 16:29-57; PMID:9048207; http://dx.doi.org/10.1007/BF02786322
8. Raghavan M, Bonagura VR, Morrison SL, Bjorkman PJ. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry 1995; 34:14649-57; PMID:7578107; http://dx.doi.org/10.1021/bi00045a005
9. Ghetie V, Ward ES. Transcytosis and catabolism of antibody. Immunol Res 2002; 25:97-113; PMID:11999172; http://dx.doi.org/10.1385/IR:25:2:097
10. Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, Starovasnik MA, Lowman HB. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 2009; 182:7663-71; PMID:19494290; http://dx.doi.org/10.4049/jimmunol.0804182
11. Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, Petkova S, Avanessian L, Choi EY, Shaffer DJ, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 2003; 170:3528-33; PMID:12646614
12. Anderson CL, Chaudhury C, Kim J, Bronson CL, Wani MA, Mohanty S. Perspective - FcRn transports albumin: relevance to immunology and medicine. Trends Immunol 2006; 27:343-8; PMID:16731041; http://dx.doi.org/10.1016/j.it. 2006.05.004
13. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu Rev Immunol 2000; 18:739-66; PMID:10837074; http://dx.doi.org/10.1146/annurev.immunol.18.1.739
14. Montoyo HP, Vaccaro C, Hafner M, Ober RJ, Mueller W, Ward ES. Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc Natl Acad Sci U S A 2009; 106:2788-93; http://dx.doi.org/10.1073/pnas.0810796106; PMID:19188594
15. Borvak J, Richardson J, Medesan C, Antohe F, Radu C, Simionescu M, Ghetie V, Ward ES. Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. Int Immunol 1998; 10:1289-98; PMID:9786428; http://dx.doi.org/10.1093/intimm/10.9.1289
16. Telleman P, Junghans RP. The role of the Brambell receptor (FcRB) in liver: protection of endocytosed immunoglobulin G (IgG) from catabolism in hepatocytes rather than transport of IgG to bile. Immunology 2000; 100:245-51; PMID:10886402; http://dx.doi.org/10.1046/j.1365-2567.2000.00034.x
17. Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Jiang W, Wroblewski VJ. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos 2007; 35:86-94; PMID:17050651; http://dx.doi.org/10.1124/dmd.106.011734
18. Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, Ober RJ, Ward ES. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 1997; 15:637-40; PMID:9219265; http://dx.doi.org/10.1038/nbt0797- 637
19. Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 2010; 184:1968-76; PMID:20083659; http://dx.doi.org/10.4049/jimmunol.0903296
20. Gurbaxani B, Dela Cruz LL, Chintalacharuvu K, Morrison SL. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol Immunol 2006; 43:1462-73; PMID:16139891; http://dx.doi.org/10.1016/j.molimm.2005.07.032
21. West AP Jr., Bjorkman PJ. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). Biochemistry 2000; 39:9698-708; PMID:10933786; http://dx.doi.org/10.1021/ bi000749m
22. Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 2002; 169:5171-80; PMID:12391234
23. Gan Z, Ram S, Vaccaro C, Ober RJ, Ward ES. Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery. Traffic 2009; 10:600-14; http://dx.doi.org/10.1111/j.1600-0854.2009.00887.x; PMID:19192244
24. Henderson LA, Baynes JW, Thorpe SR. Identification of the sites of IgG catabolism in the rat. Arch Biochem Biophys 1982; 215:1-11; PMID:7092219; http://dx.doi.org/10.1016/0003-9861(82)90272-7
25. Weisbecker U, Ibbotson GE, Livesey G, Williams KE. The fate of homologous 125I-labelled immunoglobulin G within rat visceral yolk sacs incubated in vitro. Biochem J 1983; 214:815-22; PMID:6626158
26. Thorpe SR, Baynes JW, Chroneos ZC. The design and application of residualizing labels for studies of protein catabolism. FASEB J 1993; 7:399-405; PMID:8462781
27. Boswell CA, Bumbaca D, Fielder PJ, Khawli LA. Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations. AAPS J 2012; 14:612-8; http: //dx.doi.org/10.1208/s12248-012- 9374-1; PMID:22648903
28. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 2010; 21:2153-63; PMID:21053952; http://dx.doi.org/10.1021/ bc100261d
29. Antohe F, Radulescu L, Gafencu A, Ghetie V, Simionescu M. Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. Hum Immunol 2001; 62:93-105; PMID:11182218; http://dx.doi.org/10.1016/S0198-8859(00)00244-5
30. Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil FP, Lowman HB, Fielder PJ, Prabhu S. Pharmacokinetics of humanized monoclonal antitumor necrosis factor-alpha antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 2010; 38:600-5; http://dx.doi.org/10. 1124/dmd.109.031310; PMID:20071453
31. Vaccaro C, Bawdon R, Wanjie S, Ober RJ, Ward ES. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc Natl Acad Sci U S A 2006; 103:18709-14; PMID:17116867; http://dx.doi.org/10.1073/pnas.0606304103
32. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13:1551-9; PMID:11717196; http://dx.doi.org/10. 1093/intimm/13.12.1551
33. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev 2010; 110:2858-902; http://dx.doi.org/10.1021/cr900325h; PMID:20415480
34. Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, Clark S, Ross S, Cheng E, Parsons-Reponte K, et al. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther 2012; 11:752-62; http: //dx.doi.org/10.1158/1535-7163.MCT-11-0742-T; PMID:22222630
35. Boswell CA, Mundo EE, Firestein R, Zhang C, Mao W, Gill H, Young C, Ljumanovic N, Stainton S, Ulufatu S, et al. An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2. Br J Pharmacol 2013; 168:445-57; http://dx.doi.org/10.1111/j.1476-5381. 2012.02138.x; PMID:22889168
36. Wright A, Sato Y, Okada T, Chang K, Endo T, Morrison S. In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. Glycobiology 2000; 10:1347-55; PMID:11159927; http://dx.doi.org/10.1093/glycob/10.12.1347
37. Ferl GZ, Kenanova V, Wu AM, DiStefano JJ 3rd. A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol Cancer Ther 2006; 5:1550-8; PMID:16818514; http://dx.doi.org/10. 1158/1535-7163.MCT-06-0072
38. Jaggi JS, Carrasquillo JA, Seshan SV, Zanzonico P, Henke E, Nagel A, Schwartz J, Beattie B, Kappel BJ, Chattopadhyay D, et al. Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor. J Clin Invest 2007; 117:2422-30; PMID:17717602; http://dx.doi.org/10. 1172/JCI32226
39. Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 2007; 34:687-709; PMID:17636457; http://dx.doi.org/10. 1007/s10928-007-9065-1
40. Abuqayyas L, Balthasar JP. Investigation of the role of FcγR and FcRn in mAb distribution to the brain. Mol Pharm 2013; 10:1505-13; http://dx.doi.org/10.1021/mp300214k; PMID:22838637
41. Garg A, Balthasar JP. Investigation of the influence of FcRn on the distribution of IgG to the brain. AAPS J 2009; 11:553-7; http://dx.doi.org/10. 1208/s12248-009-9129-9; PMID:19636712
42. Zhang Y, Pardridge WM. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J Neuroimmunol 2001; 114:168-72; PMID:11240028; http://dx.doi.org/10.1016/S0165-5728(01)00242-9
43. Deane R, Sagare A, Hamm K, Parisi M, LaRue B, Guo H, Wu Z, Holtzman DM, Zlokovic BV. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 2005; 25:11495-503; PMID:16354907; http://dx.doi.org/10.1523/JNEUROSCI.3697-05.2005
44. Schlachetzki F, Zhu C, Pardridge WM. Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem 2002; 81:203-6; PMID:12067234; http://dx.doi.org/10.1046/j.1471-4159.2002.00840.x
45. Kim JK, Firan M, Radu CG, Kim CH, Ghetie V, Ward ES. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol 1999; 29:2819-25; PMID:10508256; http://dx.doi.org/10.1002/ (SICI) 1521-4141(199909)29:09〈2819: :AIDIMMU2819〉3.0.CO;2-6
46. Vaughn DE, Bjorkman PJ. Structural basis of pH-dependent antibody binding by the neonatal Fc receptor. Structure 1998; 6:63-73; PMID:9493268; http://dx.doi.org/10.1016/S0969-2126(98)00008-2
47. Medesan C, Matesoi D, Radu C, Ghetie V, Ward ES. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol 1997; 158:2211-7; PMID:9036967
48. Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle NR, Kozak KR, Fourie A, Chuh J, Koppada N, Saad O, et al. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem 2011; 22:1994-2004; http://dx.doi.org/10.1021/bc200212a; PMID:21913715
49. Chizzonite R, Truitt T, Podlaski FJ, Wolitzky AG, Quinn PM, Nunes P, Stern AS, Gately MK. IL-12: monoclonal antibodies specific for the 40-kDa subunit block receptor binding and biologic activity on activated human lymphoblasts. J Immunol 1991; 147:1548-56; PMID:1715362
50. Bailer AJ. Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 1988; 16:303-9; PMID:3221328; http://dx.doi.org/10.1007/BF01062139